H.C. Wainwright Downgrades ZIOPHARM Oncology (ZIOP) to Neutral
Tweet
Share
E-mailGet Alerts ZIOP Hot Sheet
Price: $0.87 --0%
Rating Summary:
6 Buy, 9 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 7 | Down: 10 | New: 6
Rating Summary:
6 Buy, 9 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 7 | Down: 10 | New: 6
Join SI Premium – FREE
H.C. Wainwright analyst Swayampakula Ramakanth downgraded ZIOPHARM Oncology (NASDAQ: ZIOP) from Buy to Neutral.
For an analyst ratings summary and ratings history on ZIOPHARM Oncology click here. For more ratings news on ZIOPHARM Oncology click here.
Shares of ZIOPHARM Oncology closed at $5.33 yesterday.
You May Also Be Interested In
- Jefferies Downgrades ULTA Salon (ULTA) to Hold, 'Competition Intensifying & Prestige Refresh Needed'
- BofA Securities Downgrades Azul SA (AZUL) to Underperform
- Ulta stock slips as Jefferies cuts on increased competition
Create E-mail Alert Related Categories
DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
